Condition
Ph+ ALL clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Ph+ ALL clinical trials that are recruiting, at sites in 12 countries (most in China (2), Australia (1), Czechia (1)). By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 12Countries
All recruiting trials (2)
-
Low-intensity chemotherapy with olverembatinib, venetoclax and blinatumomab for newly diagnosed Philadelphia chromosome–positive ALL
This trial will test whether adding venetoclax to a low‑intensity chemotherapy plan together with continuous olverembatinib and planned blinatumomab helps people aged 14+ with newly diagnosed Ph+ ALL get deeper early molecular remission and live longer.
-
Evaluating Olverembatinib for Newly Diagnosed Ph+ ALL
This study is testing if a new drug called Olverembatinib, used with chemotherapy, can help people with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia do better than the standard treatment with Imatinib and chemotherapy.
Related topics
Quick answers
How many Ph+ ALL clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 12 countries. The most sites are in China (2 trials), Australia (1 trial), Czechia (1 trial), France (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.